Tonix Pharmaceuticals Holding Corp. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The company is a clinical-stage pharmaceutical developer with no approved products or product revenue. Its lead candidate, TNX-102 SL, was in Phase 3 development for fibromyalgia (FM) and Phase 2 development for post-traumatic stress disorder (PTSD).
Financial performance and position
Amounts below are in millions of dollars unless noted.
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue in either year |
| Research and development expense | $35.5 | $18.6 | Up 91% |
| General and administrative expense | $12.7 | $9.0 | Up 40% |
| Total operating expenses / operating loss | $48.2 | $27.7 | Loss widened |
| Net loss | $48.1 | $27.6 | Loss widened |
| Basic and diluted loss per share | $2.86 | $2.77 | Loss per share increased |
| Cash used in operating activities | $42.5 | $22.8 | Use increased |
- Liquidity: At year-end, cash and cash equivalents were $19.2 million and available-for-sale marketable securities were $23.8 million, totaling $43.0 million. Working capital was $39.7 million; total current assets were $46.4 million and current liabilities were $6.7 million.
- Cash flows and financing: Investing activities used $24.2 million, largely reflecting purchases of marketable securities. Financing activities provided $47.7 million net, primarily from common-stock offerings. Cash declined by $19.0 million during 2015.
- Debt and obligations: The balance sheet reports no borrowings; total liabilities were $6.8 million. Contractual obligations included $21.1 million of research and development commitments and $2.1 million of operating leases, mostly due within one year.
- Margins: Not meaningful because the company had no revenue or cost of goods sold.
- Capital structure: Common shares outstanding rose from 10.8 million at year-end 2014 to 18.8 million at year-end 2015, primarily following equity offerings. The company reported an accumulated deficit of $102.4 million.
- Fourth quarter: Unaudited Q4 2015 operating loss was $13.4 million, net loss was $13.4 million and loss per share was $0.71. Q4 2014 net loss was $9.0 million and loss per share was $0.83.
Material developments and outlook
- TNX-102 SL for FM: The Phase 2b BESTFIT trial missed its primary endpoint of mean pain-intensity change (p=0.172), but showed a statistically significant 30% pain-responder result (34.0% versus 20.6%; p=0.033) and improvements on certain secondary measures. The FDA accepted a 30% pain-responder endpoint for the Phase 3 program. The 500-patient AFFIRM trial was underway; the company expected topline results in Q3 2016 and planned a second Phase 3 trial, REAFFIRM, in Q2 2016. A 12-month open-label safety study was completed in August 2015.
- TNX-102 SL for PTSD: Enrollment in the Phase 2 AtEase trial was completed in December 2015; topline results were expected in Q2 2016. The company stated that two adequate, well-controlled studies and long-term safety exposure would be needed to support approval, subject to FDA requirements.
- TNX-201: After year-end, the company reported that the Phase 2 episodic tension-type headache study did not show efficacy and discontinued development on February 16, 2016.
- Other programs: TNX-301, a proposed fixed-dose combination for alcohol use disorder, remained in early development. Smallpox-vaccine and radiation-protection programs were nonclinical.
- Management outlook: The company expected research and development spending to increase significantly over the next 12–24 months. Management believed existing cash and cash equivalents would fund planned operations and trials for at least 12 months from the filing, but acknowledged that additional capital might be needed. Equity financing could dilute shareholders; inadequate funding could force program delays, reductions or cessation.
- Regulatory and development risks: TNX-102 SL remained investigational, and the anticipated 505(b)(2) pathway and timelines were not assured. Trial outcomes, FDA review, manufacturing readiness, competition, reimbursement, intellectual-property protection and reliance on third-party clinical and manufacturing providers are material risks. The filing notes the negative primary endpoint in BESTFIT despite positive secondary findings.
- Other notable items: Related-party transactions included prior acquisitions of biodefense intellectual property from entities controlled by CEO Seth Lederman, for cash and shares. The company reported an unqualified audit opinion and effective internal control over financial reporting.
Investor verification priorities
- Check subsequent filings for AFFIRM and AtEase topline results, later trial designs, and the status of any FDA interactions or applications.
- Assess the primary-endpoint miss in BESTFIT against its secondary and responder findings, and verify whether later confirmatory trials replicate benefit and safety.
- Reconcile cash burn, cash plus marketable securities, and the stated 12-month runway against subsequent spending and financing; monitor dilution and outstanding equity awards.
- Review the timing, cancellation terms and execution of the $21.1 million research and development commitments, as well as manufacturing and regulatory requirements.
- Evaluate TNX-201’s discontinuation and the company’s concentration in TNX-102 SL, alongside remaining pipeline prospects and related-party disclosures.